| Issue Date | Title | Author(s) |
| 1 | Sep-2013 | 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells | Can, G.; Akpınar, B.; Baran, Yusuf ; Zhivotovsky, B.; Olsson, M. |
| 2 | Jun-2013 | Autologous rabbit adipose tissue-derived mesenchymal stromal cells for the treatment of bone injuries with distraction osteogenesis | Sunay, Özgür; Can, Geylani; Çakır, Zeynep; Denek, Ziya; Kozanoglu, İlknur; Erbil, Güven; Yılmaz, Mustafa; Baran, Yusuf |
| 3 | 2013 | Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era | Cömert, Melda; Baran, Yusuf ; Saydam, Güray |
| 4 | May-2013 | Changes in protein profiles of multiple myeloma cells in response to bortezomib | Turan, Taylan; Şanlı Mohamed, Gülşah ; Baran, Yusuf |
| 5 | 2013 | Gossypol interferes with both type I and Type II topoisomerase activities without generating strand breaks | Şenarısoy, Müge; Cantürk, Pakize; Zencir, Sevil; Baran, Yusuf ; Topçu, Zeki |
| 6 | 2013 | Granulocytic sarcoma: a systematic review | Yılmaz, Asu Fergün; Saydam, Güray; Şahin, Fahri; Baran, Yusuf |
| 7 | Jun-2013 | Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance | Camgöz, Aylin; Gençer, Emel Başak; Ural, Ali Uğur; Baran, Yusuf |
| 8 | Apr-2013 | miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells | Fıratlıgil, Burcu ; Biray Avcı, Çığır; Baran, Yusuf |
| 9 | Feb-2013 | New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma | Kozanoğlu, İlknur; Kartal Yandım, Melis; Çinçin, Zeynep Birsu; Özdoğu, Hakan; Çakmakoğlu, Bedia; Baran, Yusuf |
| 10 | Jan-2013 | Novel agents targeting bioactive sphingolipids for the treatment of cancer | Adan Gökbulut, Aysun ; Kartal Yandım, Melis; İskender, Güniz; Baran, Yusuf |
| 11 | 2013 | Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest | Adan Gökbulut, Aysun ; Apohan, Elif; Baran, Yusuf |
| 12 | Jul-2013 | The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinibresistant chronic myeloid leukemia cells | Bozkurt, Süreyya; Özkan, Tülin; Özmen, Füsun; Baran, Yusuf ; Sunguroglu, Asuman; Kansu, Emin |
| 13 | Apr-2013 | The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy | Baran, Yusuf ; Ceylan, Çağatay ; Camgöz, Aylin |
| 14 | Jul-2013 | STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells | Kiper, Hatice Demet; Tezcanlı Kaymaz, Burçin; Adan Gökbulut, Aysun ; Selvi, Nur; Biray Avcı, Çığır; Kosova, Buket; İskender, Güniz; Kartal Yandım, Melis; Gündüz, Cumhur; Şahin, Fahri; Baran, Yusuf ; Saydam, Güray |
| 15 | Jan-2013 | Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer | Kartal Yandım, Melis; Apohan, Elif; Baran, Yusuf |
